RESUMO
We studied the effect of acetylsalicylic acid on ROS generation by platelets in patients after surgical interventions and in patients with bronchial asthma was studied. Platelets stimulated with platelet-activating factor are characterized by weak luminol-enhanced chemiluminescence in healthy people and patients after operations with laparoscopic incisions. Addition of platelet activation factor to platelet samples from patients after open abdominal surgery caused intensive chemiluminescence that was suppressed after platelet incubation with acetylsalicylic acid. At the same time, platelets of patients with aspirin-sensitive asthma did not respond to addition of platelet activating factor, but after incubation with acetylsalicylic acid, an intensive burst of chemiluminescence was detected with a maximum in 5-10 sec after the addition of a platelet-activating factor. In patients with bronchial asthma tolerant to aspirin, platelet activation factor did not induce chemiluminescence irrespective of incubation with acetylsalicylic acid.
Assuntos
Aspirina/farmacologia , Asma/sangue , Plaquetas/metabolismo , Inibidores da Agregação Plaquetária/farmacologia , Espécies Reativas de Oxigênio/metabolismo , Plaquetas/efeitos dos fármacos , Estudos de Casos e Controles , Avaliação Pré-Clínica de Medicamentos , Humanos , Laparoscopia , Ativação PlaquetáriaRESUMO
We studied efficacy ofsetegis in different doses for therapy of lower urinary tract symptoms in patients after transvesical adenomectomy (TVAE). The analysis of case histories of 41 patients after open TVPE for prostatic adenoma has shown that setegis (terazosin) is effective in therapy of urinary bladder overactivity which is present in the majority of patients after TVAE. Compared to the controls, terazosin-treated patients improved urination more noticeably. Thus, alpha-adrenoblocker segetis is effective and safe in therapy of imperative voiding disorders with symptoms of urgent incontinence in patients after TVAE. Use of this drug can significantly contribute to successful postoperative rehabilitation of postadenomectomy patients. Setegis can be recommended for wide clinical practice.
